Dubin-Johnson syndrome (DJS) is an inherited disorder characterized by conjugated hyperbilirubinemia and is caused by a deficiency of the multidrugresistance protein 2 (MRP2) located in the apical membrane of hepatocytes.
Introduction
Dubin-Johnson syndrome (DJS) is an autosomal recessive disorder manifested by chronic conjugated hyperbilirubinemia and accumulation of a dark pigment in liver parenchymal cells (1, 2) . The disorder has recently been associated with several mutations in the multidrug resistance protein 2 (MRP2) gene (3) (4) (5) (6) (7) . MRP2, also known as the canalicular multispecific organic anion transporter, is a 190 kDa integral membrane glycoprotein expressed mainly in the canalicular (apical) membrane of liver cells. It belongs to the superfamily of ATP-binding cassette (ABC) transporters, and transports endogenous and exogenous anionic conjugates from hepatocytes to the bile (8) (9) (10) (11) (12) (13) . MRP2 is one of seven known MRP's that are involved in resistance of cancer cells to chemotherapeutic drugs (13) (14) (15) (16) (17) . The MRP2 consists of 1545 amino acids and its gene is located on chromosome 10q24 (13, 14, 16, 18) . The genomic structure of the MRP2 gene exhibits a remarkable similarity to the MRP1 gene; it contains 32 exons and spans ~45 kb (6, 7) .
Since the original description of DJS, many cases have been described in different populations (19) (20) (21) (22) and a cluster of 101 patients was ascertained in Israel (23) . Sixty three percent of the Israeli patients were of Iranian-Jewish origin, and 9 percent were of Moroccan-Jewish origin.
Expression of recombinant MRP2 in mammalian cell lines provides an important tool for functional characterization of this transporter. The activity of MRP2 has been evaluated by uptake of radiolabelled substrates into membrane vesicles prepared from MRP2-transfected cells (24) (25) (26) (27) , or by measurements of the accumulation of fluorescent compounds in intact cells (28) (29) (30) (31) (32) (33) . The fluorescent anion 5-carboxyfluorescein (CF; 34) has been used as a substrate for transport by MRP1 and MRP2 (32, 35, 36) . The results obtained by these measurments have a relatively poor temporal resolution and require transfection with high efficiency or development of stable cell lines.
In this study we identified two novel mutations causing DJS in the Iranianand Moroccan-Jewish patients, respectively and obtained evidence for specific founder effects which account for the observed clusters. Both mutations were 
Methods

Patients
Most patients with DJS were previously ascertained (23) and have been followed for more than 3 decades. The diagnosis was based on the finding of chronic or intermittent conjugated hyperbilirubinemia, and on either finding in liver biopsy material the typical pigment in hepatocytes, or a predominance of coproporphyrin I urinary excretion (37) . A total of 35 patients of 24 unrelated families were included in the study. Twenty two were of Iranian Jewish origin (13 families), 5 were of Moroccan Jewish origin (4 families), 2 were offspring of a Moroccan-Jewish mother and an Iranian-Jewish father, 3 were of AshkenaziJewish origin (3 families) and 3 were of Turkish-, Kurdish-and Afghani-Jewish origins, respectively.
Control subjects
Control subjects were patients consecutively admitted to the Sheba Medical center, or healthy individuals belonging to its personnel. Definition of the ethnic origin of each subject was based on the country of birth of the individual's 4 grandparents. The human subject ethics committee of Sheba Medical Center approved the performance of the study.
Materials and antibodies
LipofectAMINE and geneticin (G418) were obtained from Life 
Plasmids
The human MRP2 expression vector, pcDNA3.1/MRP2 was a gift from Professor D. Keppler and was described before (27) . Green fluorescent (GFP)-expressing plasmid was purchased from Life Technologies, Inc.
Amplification of genomic DNA
Genomic DNA was extracted from peripheral blood leukocytes by the desalting procedure (39) . Polymerase chain reaction (PCR) was used to amplify each of the 32 exons of the MRP2 gene and their intronic-exonic boundaries. Primers were designed according to intronic sequences flanking the exons (6, 7) and are presented in Table 1 . PCR was performed in a 20 µl 
Identification of sequence alterations
PCR fragments were sequenced either directly or after subcloning into pGEM-T vector using pGEM-T vector System (Promega, Madison, WI) and transformation into JM109 competent cells (Promega). Plasmid DNA was isolated using Wizard TM Plus Minipreps DNA Purification System (Promega).
metaphor gels (FMC-Bioproducts, Rockland, ME). Allele frequencies for identified mutations and polymorphisms were determined in patients with DJS and in control populations.
Haplotype analysis and assessment of founder effect
Haplotypes of informative alleles from patients with DJS and controls were determined. Assessments of founder haplotypes were based on χ 2 analysis.
Site-directed mutagenesis
Mutations were introduced into the pcDNA3.1/MRP2 vector using the Stratagene QuikChangeTM Site-Directed Mutagenesis Kit (La Jolla, CA).
Incorporation of the mutations was verified by DNA sequencing. Two sets of primers were used to introduce the I1173F mutation:1) the forward primer (5'-CAGGTTTGCCAGTTTTCCGTGCCTTTGAGC-3') and the reverse primer (5'-GCTCAAAGGCACGGAAAACTGGCAAACCTG-3'); 2) the forward primer (5'-CCGTATCAGGTTTGCCAGTTTTCCGTGCCTTTGAGC-3') and the reverse primer (5'-GCTCAAAGGCACGGAAAACTGGCAAACCTGATACGG-3'). This was done to insure that low expression of this construct was not due to unexpected interference in any region of the vector except for the desired mutation. The primers used to introduce the R1150H mutation are the forward primer (5'-GCCAGCTGAGGCATCTGGACTCTGTCACCAG-3') and the reverse primer (5'-CTGGTGACAGAGTCCAGATGCCTCAGCTGGC-3'). All procedures were as suggested by the manufacturer. Positive clones were selected on ampcillin agar plates and all clones were verified by sequencing. At least three clones of each mutant were analysed for activity and all six clones of the I1173F mutant were analysed for expression by western blot. 
Cell culture and transfections
Results
Identification of candidate mutations in DJS patients
Screening of all 32 exons of the MRP2 gene in an Iranian-Jewish patient disclosed a 3517(A T) transition in exon 25 predicting an l1173F substitution.
The mutation was detectable by restriction analysis of nested PCR performed as follows: First, exon 25 was amplified by the forward and reverse primers depicted in Table 1 , then nested PCR was carried out using a mutated forward primer ( The estimated allele frequency of the mutation in the general Moroccan-Jewish population was 0.9% (95% confidence interval 0.24 to 2.27%) ( Table 2) . were recently published (40) . Methods were devised for simple detection of these four polymorphisms by PCR and restriction analysis (Fig.2) . Table 2 shows the allele frequencies of the four dimorphisms in Iranian-, Moroccan-, and Ashkenazi-Jews. A pronounced difference was observed for the rare 842(G A) dimorphism; in Moroccan-Jews its frequency was 6 fold higher than in AshkenaziJews and 9 fold higher than in Iranian-Jews.
Identification of novel polymorphisms in the MRP2 gene
Founder effect for the Iranian-Jewish 3517(A T) mutation
Haplotype analysis disclosed that all 26 alleles of 13 unrelated IranianJewish patients carried the same haplotype (-24C, 842G, 1249A, IVS29-35A), whereas none of 144 informative alleles (out of 168 examined) of control Iranian
Jews carried the same haplotype ( Table 3 ). The common haplotype among Iranian-Jewish controls was -24C, 842G, 1249G, IVS29-35G; it accounted for 63% of the alleles. Statistical analysis yielded highly significant differences in the haplotype distribution between patients and controls (χ 2 =271, P<0.0001).
The 3517(A T) mutation and the four dimorphisms were examined in a large Iranian-Jewish family. As can be seen in Fig. 3 
Carboxylfluorescein transport assay of MRP2 activity
A new procedure was developed to estimate MRP2 activity with high Upon removal of probenecid, CF efflux from control cells remained slow ( Figure   4A ). By contrast, an almost immediate high rate of CF efflux was seen in cells expressing WT-MRP2 (Fig 4B) . MRP2-mediated CF efflux followed a single exponential with a rate constant of about 600 sec -1 . Figure 4C shows that the effect of probenecid was completely reversible.
Removal and addition of probenecid resulted in an immediate onset and inhibition of CF transport. Fig 4D illustrates Figure 4E shows that 10 µM cyclosporine A inhibited MRP2-dependent CF efflux in an irreversible manner.
Carboxyfluorescein transport of mutants MRP2
Transfected HEK-293 cells expressing the I1173F-and R1150H-MRP2 mutants were used to study the effect of the mutations on CF transport.
Experiments were performed with each mutant and results were always compared to efflux by WT-MRP2 and control, GFP-transfected cells. A typical CF efflux from control, mutant and WT-MRP2 proteins is illustrated in Figure 5 . Cells transfected with either I1173F- (Fig 5C) or R1150H-MRP2 (Fig 5D) showed a slow efflux of CF, which was similar to that measured in control cells (Fig 4A,   5A ), while cells transfected with WT-MRP2 cells displayed a robust efflux (Fig 4B , 
Cellular localization of WT and mutants MRP2
The significant amount of the 175 kDa band found in cells expressing I1173F-MRP2 suggests that processing of MRP2 was affected by this mutation.
Consequently, it was of interest to determine the intracellular localization of WT and MRP2 mutants. The results are shown in Figure 7 . In cells transfected with WT-MRP2 and in R1150H-MRP2 the protein was localized at the plasma membrane (Fig 7A and 7B ) and a Golgi-like structure. This sugested that processing and targeting of the R1150H-MRP2 mutant was normal. In contrast,
I1173F-MRP2
showed largely a reticular pattern of staining (Fig 7C) . Table 2 ), indicating that these mutations are unique for these specific populations. Both mutations strongly correlate with DJS as indicated by the following evidence: 1) twenty-two Iranian-Jewish patients were homozygous for the 3517(A T) mutation and 7 obligatory carriers from one kindred were heterozygous for the mutation (Fig 3) , and all 5 patients of Moroccan-Jewish origin were homozygous for the 3449(G A) mutation; 2) two patients of mixed Iranian-and Moroccan Jewish origin were compound heterozygotes for both mutations (Fig 1); 3 In a previous study we estimated that 1:1300 Iranian-Jews residing in Israel are affected by DJS, which implied a 5.4 percent prevalence of heterozygotes in this population (23) . In the present study screening of 486 control Iranian-Jewish alleles for the 3517(A T) mutation yielded an almost identical result. Thus, the frequency of the mutant allele was 2.9 percent, which is consistent with a 5.8 percent prevalence of heterozygotes (Table 2 ). In 452 Moroccan-Jewish control alleles the prevalence of the 3449(G A) mutation was only 0.9%, which predicted a 1.8% prevalence of heterozygotes in this population ( Table 2) With this assay we showed that both, I1173F and R1150H mutations impaired the MRP2 activity (Fig 5) . However, this was due to a different effect by each of the mutations (see below).
Immunoblot analysis revealed that MRP2 exists in at least two forms: a mature glycosylated form of about 190 kDa apparent molecular mass and an immature unglycosilated form of about 175 kDa apparent molecular mass.
Similar observations were made for other ABC transporters such as MRP1 (46), P-glycoprotein (47) and CFTR (48) . The R1150H mutation had no apparent effect on the relative amount of each MRP2 forms. In contrast, the I1173F mutation gave rise to a markedly reduced relative amount of the 190 kDa band and an increased relative amount of the 175 kDa form. Furthermore, the total amount of I1173F-MRP2 that was expressed was substantially decreased (Fig 6) which suggests enhanced intracellular degradation, due to mistargetting and misfolding of the mutant protein. Indeed, immunolocalization of the different constructs showed that WT and R1150H-MRP2 were properly targetted to the plasma membrane, whereas I1173F-MRP2 remained largely confined to the ER.
Expression studies have provided a useful tool for studying the underlying mechanism causing DJS as was shown for the 4175del6 mutation (49) . Our expression studies suggest that the I1173F mutation causes impaired maturation of MRP2, mislocalization probably to the ER and augmented degradation, whereas the R1150H mutation does not affect the maturation and localization, but impairs the MRP2 transport activity. Interestingly, two site directed mutations which replaced Arg by Ala in the predicted third transmembrane region of MRP2 (R1210A and R1257A), were shown to cause normal expression but impaired transport activity of MRP2 (33) . This may imply that this region is important for MRP2 transport activity and that Arg residues in this region play an important role in its function.
In summary, Our results provide strong evidence that two ancestral mutations cause DJS in two clusters of Israeli patients and provide a probable mechanism for their effect. The new transport assay that we devised can be useful in studying additional mutations, in particular those with normal expression.
Moreover, the assay may be used with other fluorescent substrates in order to better characterize transport activity of MRP2.
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